Comparing the protein expression values of CD22 with Mucin 1 (MUC1) (another favorable CAR-T target for TNBC) in normal human tissues using data from The Human Protein Atlas database (www.proteinatlas.org/; accessed on 15 December 2022) reveals that CD22 expressed in fewer normal tissues as compared to MUC1, which suggests that CD22 as CAR-T target in TNBC may result in less off-tumor toxicity. Here, CD22 is linked to neoplasm.